Jo Van Ginderachter

This inventor holds 6 USPTO granted patents and 7 published patent applications, plus 1 CIPO patent and 2 EPO patents. Top assignees: Vrije Universiteit Brussel, Vib Vzw, University of Ghent. Active years: 2015-2024.

USPTO Granted Patents = 6 (Patent Applications = 7)

% Patents Active = 100.0

CIPO Patents = 1 (Patent Applications = 5)

EPO Patents = 2 (Patent Applications = 10)

Average Co-Inventor Count = 6.6

ph-index = 2

Forward Citations = 17(Granted Patents)

Company Filing History:

6 out of 190

Vrije Universiteit Brussel

where one patent can have more than one assignee

Years Active: 2015-2024

Loading Chart...

6 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11858960 - Human PD-L1-binding immunoglobulins (2024-01-02),

2. 11098113 - Immunoglobulin single variable domains directed against macrophage migration inhibitory factor (2021-08-24),

3. 11083751 - Tumor-associated dendritic cell preparations and uses thereof (2021-08-10),

4. 9913920 - Targeting and in vivo imaging of tumor-associated macrophages (2018-03-13),

5. 9556273 - Anti-macrophage mannose receptor single variable domains for targeting and in vivo imaging of tumor-associated macrophages (2017-01-31),

6. 9101674 - Targeting and in vivo imaging of tumor-associated macrophages (2015-08-11),

Title: Jo Van Ginderachter: Innovator in Immunology

Introduction

Jo Van Ginderachter is a prominent inventor based in Ninove, Belgium. He has made significant contributions to the field of immunology, particularly through his innovative patents. With a total of 6 patents, his work focuses on developing novel therapeutic and diagnostic agents.

Latest Patents

One of his latest patents is titled "Human PD-L1-binding immunoglobulins." This invention relates to polypeptides that comprise an immunoglobulin domain, which binds to human Programmed Death Ligand-1 (huPDL1). These polypeptides have applications as medicaments or diagnostic agents, such as immunotraders. Another notable patent is "Immunoglobulin single variable domains directed against macrophage migration inhibitory factor." This invention involves immunoglobulin single variable domains that bind to MIF, including polypeptides that consist of these domains. It also covers nucleic acids encoding such polypeptides and their pharmaceutical compositions for prophylactic, therapeutic, or diagnostic purposes.

Career Highlights

Throughout his career, Jo Van Ginderachter has worked with esteemed institutions, including Vrije Universiteit Brussel and VIB VZW. His research has significantly advanced the understanding of immune responses and therapeutic interventions.

Collaborations

Jo has collaborated with notable colleagues such as Patrick De Baetselier and Damya Laoui, contributing to various research projects and innovations in immunology.

Conclusion

Jo Van Ginderachter's contributions to immunology through his patents and collaborations highlight his role as a leading inventor in the field. His work continues to pave the way for advancements in medical treatments and diagnostics.